SHUTTLE PHARMACEUTICALS HOLD (SHPH) Stock Price, Quote, News and Overview
NASDAQ:SHPH - Nasdaq - US8256933024 - Common Stock - Currency: USD
SHPH Quote, Performance and Key Statistics
3.81
-0.13 (-3.3%)
The current stock price of SHPH is 3.81 USD. In the past month the price increased by 5.83%. In the past year, price decreased by -95.86%.
SHPH Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.43 | 334.31B | ||
| AMGN | AMGEN INC | 14.2 | 158.50B | ||
| GILD | GILEAD SCIENCES INC | 13.98 | 134.62B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | N/A | 118.08B | ||
| REGN | REGENERON PHARMACEUTICALS | 12.24 | 58.58B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 41.79B | ||
| ARGX | ARGENX SE - ADR | 98.19 | 34.47B | ||
| ONC | BEONE MEDICINES LTD-ADR | 7.53 | 31.88B | ||
| BNTX | BIONTECH SE-ADR | N/A | 26.45B | ||
| SMMT | SUMMIT THERAPEUTICS INC | N/A | 19.46B | ||
| INSM | INSMED INC | N/A | 19.46B | ||
| NTRA | NATERA INC | N/A | 18.97B |
Related stock screener links
About SHPH
Company Profile
Shuttle Pharmaceuticals Holdings, Inc. is a clinical stage pharmaceutical company, which engages in the development of novel therapies for cancer. The company is headquartered in Gaithersburg, Maryland and currently employs 9 full-time employees. The company went IPO on 2022-08-31. The firm is focused on improving the outcomes of cancer patients treated with radiation therapy (RT). The company is developing a pipeline of products designed to address cancer therapies as well as to extend to the new applications of radiation therapy. Its product candidates include Ropidoxuridine (IPdR), Ropidoxuridine and Tipracil (IPdR/TPI), SP-1-161, SP-2-225, and SP-1-303. Ropidoxuridine (IPdR) is its lead candidate radiation sensitizer for use in combination with RT to treat brain tumors (glioblastoma) and sarcomas. Ropidoxuridine and Tipracil (IPdR/TPI) is undergoing preclinical development for use as a radiation sensitizer for rectal cancers. SP-1-161 is a pre-clinical candidate lead histone deacetylase (HDAC) inhibitor, a radiation sensitizing candidate product. SP-2-225 is a pre-clinical class II b selective HDAC inhibitor that affects histone deacetylase HDAC6.
Company Info
SHUTTLE PHARMACEUTICALS HOLD
401 Professional Drive, Suite 260
Gaithersburg MARYLAND US
Employees: 8
Phone: 12404034212
SHUTTLE PHARMACEUTICALS HOLD / SHPH FAQ
What is the stock price of SHUTTLE PHARMACEUTICALS HOLD today?
The current stock price of SHPH is 3.81 USD. The price decreased by -3.3% in the last trading session.
What is the ticker symbol for SHUTTLE PHARMACEUTICALS HOLD stock?
The exchange symbol of SHUTTLE PHARMACEUTICALS HOLD is SHPH and it is listed on the Nasdaq exchange.
On which exchange is SHPH stock listed?
SHPH stock is listed on the Nasdaq exchange.
What is SHUTTLE PHARMACEUTICALS HOLD worth?
SHUTTLE PHARMACEUTICALS HOLD (SHPH) has a market capitalization of 4.08M USD. This makes SHPH a Nano Cap stock.
How many employees does SHUTTLE PHARMACEUTICALS HOLD have?
SHUTTLE PHARMACEUTICALS HOLD (SHPH) currently has 8 employees.
What are the support and resistance levels for SHUTTLE PHARMACEUTICALS HOLD (SHPH) stock?
SHUTTLE PHARMACEUTICALS HOLD (SHPH) has a resistance level at 3.9. Check the full technical report for a detailed analysis of SHPH support and resistance levels.
Should I buy SHUTTLE PHARMACEUTICALS HOLD (SHPH) stock?
There is no straightforward answer here. It depends on your investment strategy as different types of investors will look at different aspects. In any case it is important to make an informed decision and these pages can help you forming an opinion:
- The Technical Analysis (TA) tab contains a technical analysis of SHPH, looking at technical quality and support and resistance levels
- The Fundamental Analysis (FA) tab contains a fundamental analysis of SHPH, evaluating the profitability, health, valuation and growth aspects
- SHUTTLE PHARMACEUTICALS HOLD (SHPH) Price Target Forecast and Analysts Ratings to understand what professional analysts say.
- SHUTTLE PHARMACEUTICALS HOLD (SHPH) Sales and EPS estimates to see what analysts future expectations are.
- SHUTTLE PHARMACEUTICALS HOLD (SHPH) Income, Balance Sheet and Cash Flow statements to dive into the historical financials.
- SHUTTLE PHARMACEUTICALS HOLD (SHPH) Insider and Institutional Ownership to learn about the owners and their transactions.
- SHUTTLE PHARMACEUTICALS HOLD (SHPH) Stock Chart to make your own analysis
- SHUTTLE PHARMACEUTICALS HOLD (SHPH) Latest news and press-releases to stay up to date.
Does SHUTTLE PHARMACEUTICALS HOLD (SHPH) stock pay dividends?
SHPH does not pay a dividend.
What is the Price/Earnings (PE) ratio of SHUTTLE PHARMACEUTICALS HOLD (SHPH)?
SHUTTLE PHARMACEUTICALS HOLD (SHPH) does not have a PE ratio as the earnings reported over the last twelve months were negative (-79.65).
SHPH Technical Analysis
ChartMill assigns a technical rating of 1 / 10 to SHPH. When comparing the yearly performance of all stocks, SHPH is a bad performer in the overall market: 98.95% of all stocks are doing better.
SHPH Financial Highlights
Over the last trailing twelve months SHPH reported a non-GAAP Earnings per Share(EPS) of -79.65. The EPS increased by 9.87% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -364.87% | ||
| ROE | -1289.63% | ||
| Debt/Equity | 1.23 |